🇺🇸 FDA
Pipeline program

Pembrolizumab/Vibostolimab

7684A-003

Phase 3 mab completed

Quick answer

Pembrolizumab/Vibostolimab for Lung Neoplasms is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Lung Neoplasms
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials